Trial Profile

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AI 081 (Primary)
Indications Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms BIPAVE-001
Sponsors OncoC4

Most Recent Events

09 Apr 2026 Planned number of patients changed from 204 to 387.
09 Apr 2026 Planned primary completion date changed from 30 Jun 2026 to 30 Jun 2027.
22 Jul 2025 According to OncoC4 media release, the study is being carried out in the United States with 11 clinical sites actively enrolling patients. The Chinese regulatory agency also cleared the study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com